



## SMS Lifesciences India Limited

### Registered & Corporate Office :

Plot No. 19-III, Road No. 71,  
Opp. Bharatiya Vidya Bhavan Public School,  
Jubilee Hills, Hyderabad - 500 096, Telangana, INDIA.  
Tel : +91-040-6628 8888, Fax : +91-40-2355 1401  
CIN : L74930TG2006PLC050223  
Email : info@smslife.in, Website : www.smslife.in

February 13, 2025

To

**BSE Limited,**

Listing Department, P J Towers,

Dalal Street,

Mumbai – 400 001.

**Scrp code: 540679**

Through: BSE Listing Center

**National Stock Exchange of India Limited,**

Listing Department, "Exchange Plaza",

Bandra-Kurla Complex, Bandra (E),

Mumbai - 400 051.

**Trading Symbol: SMSLIFE**

Through: NEAPS Portal

**SUB: INTEGRATED FILING (FINANCIAL)**

**Ref: SEBI Circular no. SEBI/HO/CFD/CFD-PoD2/CIR/P/2024/185 dated 31.12.2024 read with  
BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025/02 dated 02.01.2025.**

Dear Sir/Madam,

With reference to the above cited subject, we are submitting herewith the Integrated Filing (Financial) of SMS Lifesciences India Limited ("Company") for the quarter and nine months ended December 31, 2024.

The above information is also available on the website of the Company [www.smslife.in](http://www.smslife.in)

Kindly take the same on record and suitably disseminate it to all concerned.

**For SMS Lifesciences India Limited**

  
**Trupti Ranjan Mohanty**  
Company Secretary



Please note that this information is submitted to Stock Exchange(s) within 24 hours from the Board meeting as per aforesaid circulars.

A. Financial Results

**SMS LIFESCIENCES INDIA LIMITED**

(CIN: L74930TG2006PLC050223)

Regd. Office: Plot No.19-III, Opp. BVBP School, Road No.71, Jubilee hills, Hyderabad - 500 096

Tel:+91-40-6628 8888, Fax:91-40-2355 1401, Email: info@smslife.in

**Standalone Statement of Un-audited Financial Results for the Quarter and Nine Months Ended 31st December, 2024**

(Rs. In Lakhs)

S.No	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	31.03.2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue From Operations	8,287.65	7,849.62	7,122.74	24,794.33	21,362.79	30,000.16
2	Other Income	6.13	125.58	64.04	174.60	155.81	383.68
3	<b>Total Revenue</b>	<b>8,293.78</b>	<b>7,975.20</b>	<b>7,186.78</b>	<b>24,968.93</b>	<b>21,518.60</b>	<b>30,383.84</b>
4	<b>Expenses</b>						
	(a) Cost of Materials Consumed	4,313.83	3,759.74	4,270.72	12,548.49	12,368.29	16,119.02
	(b) Changes in Inventories	(330.67)	125.67	(696.97)	(116.96)	(923.12)	97.57
	(c) Manufacturing Expenses	1,488.81	1,261.64	1,291.99	4,144.23	3,679.99	5,052.92
	(d) Employee Benefits Expense	1,124.39	1,089.82	1,044.83	3,332.13	3,062.73	4,092.41
	(e) Finance Cost	195.57	192.46	204.46	603.91	634.25	890.23
	(f) Depreciation and Amortization Expense	256.35	257.07	254.58	763.44	762.91	1,025.35
	(g) Other Expenses	384.53	432.76	310.04	1,022.98	813.14	1,195.11
	<b>Total Expenses - (a to g)</b>	<b>7,432.81</b>	<b>7,119.16</b>	<b>6,679.65</b>	<b>22,298.22</b>	<b>20,398.19</b>	<b>28,472.61</b>
5	<b>Profit Before Tax (3-4)</b>	<b>860.97</b>	<b>856.04</b>	<b>507.13</b>	<b>2,670.71</b>	<b>1,120.41</b>	<b>1,911.23</b>
6	<b>Tax Expenses</b>						
	(1) (i) Current Tax	250.00	250.00	150.00	800.00	330.00	425.00
	(ii) Relating to Earlier Year	(18.87)	-	-	(18.87)	-	(19.75)
	(2) Deferred Tax	7.09	5.21	25.68	20.00	77.20	199.44
		<b>238.22</b>	<b>255.21</b>	<b>175.68</b>	<b>801.14</b>	<b>407.20</b>	<b>604.69</b>
7	<b>Net Profit / (Loss) for the Period (5-6)</b>	<b>622.75</b>	<b>600.83</b>	<b>331.45</b>	<b>1,869.57</b>	<b>713.21</b>	<b>1,306.54</b>
8	Other Comprehensive Income (OCI):						
	Items that will not be reclassified to profit or Loss:	(18.89)	(17.43)	2.13	(52.30)	5.83	(58.11)
	Income Tax effect on the above	(5.50)	(5.07)	0.62	(15.23)	1.70	(16.92)
		<b>(13.39)</b>	<b>(12.36)</b>	<b>1.51</b>	<b>(37.07)</b>	<b>4.13</b>	<b>(41.19)</b>
9	<b>Total Comprehensive Income for the period (7+8)</b>	<b>609.36</b>	<b>588.47</b>	<b>332.96</b>	<b>1,832.50</b>	<b>717.34</b>	<b>1,265.35</b>
10	Earnings Per Equity Share of Rs.10/- each						
	Basic / Diluted (not annualised)	20.60	19.87	10.96	61.84	23.59	43.22
	Paid-up equity share capital (Face Value of Rs.10/- each)	302.33	302.33	302.33	302.33	302.33	302.33
11	Reserves excluding Revaluation Reserve						
	as per balance sheet of previous accounting year						17,320.48

For SMS Lifesciences India Limited

TVVSN Murthy  
Managing Director  
DIN:00465198

**Notes:**

- 1 The above standalone Financial Results have been reviewed and recommended by the Audit Committee on 12th February, 2025 and have been approved by the Board of Directors at its meeting held on 12th February, 2025. The statutory auditors of the Company have carried out limited review of Standalone financial results for the quarter and nine months ended 31st December, 2024 and expressed unmodified opinion thereon.
- 2 The standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 3 The Company is engaged in manufacturing of Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS108.
- 4 Figures for the previous period have been reclassified / regrouped wherever necessary to conform to current period's classification.

Place: Hyderabad  
Date : 12-02-2025

**For SMS Lifesciences India Limited**

**TVVSN Murthy**  
**Managing Director**  
**DIN:00465198**

**Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended**

**Review Report to  
The Board of Directors  
SMS Lifesciences India Limited**

We have reviewed the accompanying statement of unaudited standalone financial results of **SMS Lifesciences India Limited** ("the Company"), for the quarter ended 31<sup>st</sup> December 2024 ("the statement"), attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (the "Listing Regulations").

This statement which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 (Ind AS 34) "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express conclusion on the Statements based on our review.


We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by Independent Auditor of Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statements are free of material misstatement. A review of the interim financial information consists of making inquiries primarily of company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.


Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ("Ind AS") specified under Section 133 of Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad  
Date: 12.02.2025

UDIN: 25026548BMLENA4043

For Rambabu & Co.,  
Chartered Accountants  
Reg. No.0029765

  
GVL Prasad  
Partner  
M.No. 026548



**SMS LIFESCIENCES INDIA LIMITED**

(CIN: L74930TG2006PLC050223)

Regd. Office: Plot No.19-III, Opp. BVBP School, Road No.71, Jubilee Hills, Hyderabad - 500 096

Tel:+91-40-6628 8888, Fax:91-40-2355 1401, Email: info@smslife.in

**Consolidated Statement of Un-audited Financial Results for the Quarter and Nine Months Ended 31st December, 2024**

(Rs. In Lakhs)

S.No	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	31.03.2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue From Operations	8,460.10	7,846.19	7,205.33	25,561.11	21,596.69	30,595.84
2	Other Income	5.74	203.85	58.18	252.07	146.60	382.81
3	<b>Total Revenue</b>	<b>8,465.84</b>	<b>8,050.04</b>	<b>7,263.51</b>	<b>25,813.18</b>	<b>21,743.29</b>	<b>30,978.65</b>
4	<b>Expenses</b>						
	(a) Cost of Materials Consumed	3,943.18	3,501.48	3,919.20	11,716.78	11,672.02	15,018.83
	(b) Changes in Inventories	(383.58)	76.07	(790.45)	(247.96)	(934.93)	97.32
	(c) Manufacturing Expenses	1,757.54	1,469.39	1,483.14	4,860.52	4,130.82	5,763.11
	(d) Employee Benefits Expense	1,460.14	1,408.77	1,331.11	4,306.81	3,876.70	5,225.84
	(e) Finance Cost	213.79	213.55	233.84	667.83	731.96	1,015.67
	(f) Depreciation and Amortization Expense	375.69	376.26	372.55	1,119.83	1,115.54	1,493.76
	(g) Other Expenses	407.37	534.12	333.08	1,163.23	876.70	1,379.45
	<b>Total Expenses - (a to g)</b>	<b>7,774.13</b>	<b>7,579.64</b>	<b>6,882.47</b>	<b>23,587.04</b>	<b>21,468.81</b>	<b>29,993.98</b>
5	<b>Profit Before Tax (3-4)</b>	<b>691.71</b>	<b>470.40</b>	<b>381.04</b>	<b>2,226.14</b>	<b>274.48</b>	<b>984.67</b>
6	<b>Tax Expenses</b>						
	(1) (i) Current Tax	250.00	238.00	150.00	800.00	330.00	425.00
	(ii) Relating to Earlier Year	(18.87)	-	-	(18.87)	-	(19.75)
	(2) Deferred Tax	(24.73)	(97.63)	(181.28)	(79.96)	(40.82)	(53.36)
		<b>206.40</b>	<b>140.37</b>	<b>(31.28)</b>	<b>701.17</b>	<b>289.18</b>	<b>351.89</b>
7	<b>Net Profit / (Loss) for the Period (5-6)</b>	<b>485.31</b>	<b>330.03</b>	<b>412.32</b>	<b>1,524.97</b>	<b>(14.70)</b>	<b>632.78</b>
8	<b>Other Comprehensive Income/(Loss) (OCI):</b>						
	(A) Items that will not be reclassified to statement of Profit & Loss						
	Remeasurement of post-employment benefit obligations	(20.80)	(19.17)	1.08	(57.53)	2.96	(63.86)
9	Income Tax effect on the above	(5.99)	(5.53)	0.35	(16.59)	0.95	(18.42)
10	Other Comprehensive Income/(Loss) after tax for the Period / Year (8-9)	(14.81)	(13.64)	0.73	(40.94)	2.01	(45.44)
11	<b>Total comprehensive Income for the period/year (9+12)</b>	<b>470.50</b>	<b>316.39</b>	<b>413.05</b>	<b>1,484.03</b>	<b>(12.69)</b>	<b>587.34</b>
	<b>Profit for the year attributable to:</b>						
	Equity holders of the parent	546.55	467.26	430.40	1,713.62	318.87	909.28
	Non-controlling interest	(61.24)	(137.23)	(18.08)	(188.65)	(333.57)	(276.50)
	<b>Total comprehensive income for the year attributable to:</b>						
	Equity holders of the parent	532.31	454.14	431.44	1,674.23	321.72	865.54
	Non-controlling interest	(61.81)	(137.75)	(18.39)	(190.20)	(334.41)	(278.20)
12	Earning Per Equity Share of Rs.10/- each						
	Basic / Diluted (not annualised)	18.08	15.46	14.24	56.68	10.55	30.08
13	Paid-up equity share capital (Face Value of Rs.10/- each)	302.33	302.33	302.33	302.33	302.33	302.33
14	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year						17,379.09

For SMS Lifesciences India Limited

TVVSN Murthy  
Managing Director  
DIN:00465198

**Notes:**

- 1 The above Consolidated Financial Results have been reviewed and recommended by the Audit Committee on 12th February, 2025 and have been approved by the Board of Directors at its meeting held on 12th February, 2025. The statutory auditors of the Company have carried out the limited review of Consolidated financial results for the quarter and nine months ended 31st December, 2024 and expressed unmodified conclusion thereon.
- 2 The consolidated financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
- 3 The Consolidated financial results are prepared by applying Ind AS-110 "Consolidated Financial Statements", includes financial results of Mahi Drugs Private Limited, a subsidiary with 60% stake.
- 4 The Subsidiary Company has successfully completed USFDA inspection, in the month of January, 2025, with no observations. The Consolidated entity is engaged in manufacturing of Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS108.
- 5 Figures for the previous period have been reclassified / regrouped wherever necessary to conform to current period's classification.

Place: Hyderabad  
Date : 12-02-2025

**For SMS Lifesciences India Limited**

  
**TVVSN Murthy**  
**Managing Director**  
**DIN:00465198**

**Independent Auditor's Review Report on review of Interim Consolidated Financial Results**

To the Board of Directors of  
**SMS Lifesciences India Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial results of **SMS Lifesciences India Limited** ("the Parent") and its subsidiary (the Parent and its subsidiary together referred to as "the Group") for the quarter ended 31<sup>st</sup> December, 2024 (the "statement"), being submitted by the parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.


2. This statement is the responsibility of the Parent's Management and has been approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting (Ind AS 34)", prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial information performed by the Independent Auditor of the Entity*, issued by The Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the result of the following entities

- a. M/s.SMS Lifesciences India Limited
- b. M/s. Mahi Drugs Private Limited



5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the wSEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The consolidated unaudited financial results includes the interim financial statements/ financial information of above subsidiary, whose interim financial statements / financial information reflect total revenue of Rs.984.59 Lakhs, total net loss after tax of Rs.153.11 Lakhs and total comprehensive Loss of Rs.154.52 Lakhs for the Quarter ended 31 December, 2024, as considered in the Statement. According to the information and explanations given to us by the Management, the interim financial statements / financial information is not material to the Group. Our conclusion on the Statement is not modified in respect of our reliance on the interim financial statements / financial information certified by the Management.

Place: Hyderabad


Date: 12.02.2025

UDIN: 25026548BMLENB5002

For Rambabu & Co.,

Chartered Accountants

Reg. No.002976S

  
GVL Prasad  
Partner

M. No. 026548





**B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC.**

Not Applicable.

**C. FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES:**

Not Applicable, No Default

**D. FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS (applicable only for half-yearly filings i.e., 2<sup>nd</sup> and 4<sup>th</sup> quarter) :**

Not Applicable for 3<sup>rd</sup> Quarter.

**E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG-WITH ANNUAL AUDITED FINANCIAL RESULTS (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4<sup>th</sup> quarter) –**

Not Applicable for 3<sup>rd</sup> Quarter.

\*\*\*\*\*

